Self-inactivating Gammaretroviral Vectors for Gene Therapy of X-linked Severe Combined Immunodeficiency
Open Access
- 1 March 2008
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 16 (3) , 590-598
- https://doi.org/10.1038/sj.mt.6300393
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cellsBlood, 2007
- Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivoJournal of Clinical Investigation, 2007
- Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapyJournal of Clinical Investigation, 2007
- Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicityBlood, 2006
- Severe combined immunodeficiency. A model disease for molecular immunology and therapyImmunological Reviews, 2005
- LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1Science, 2003
- A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2003
- Plat-E: an efficient and stable system for transient packaging of retrovirusesGene Therapy, 2000
- Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor $gamma; chainMolecular Immunology, 1998
- Generation and Analysis of Interleukin-4 Deficient MiceScience, 1991